Business
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the European Medicines Agency (EMA) approved the C
About this update from Cullinan Therapeutics, Inc.
[{"type":"image","alt":"Cullinan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cullinan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuI0MWklffj9jltO0FlcBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05","width":300,"height":157}},"lazy":false},{"type":"text","content":"Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025","length":145,"tagName":"p"},{"type":"text","content":"CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus ","length":97,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the European Medicines Agency (EMA) approved the Company’s Clinical Trial Application (CTA) for CLN-978.","length":315,"tagName":"p"},{"type":"text","content":"The Phase 1 clinical trial will assess CLN-978 in patients with active, difficult-to-treat rheumatoid arthritis meeting the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) Classification Criteria. This open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics, and effects of CLN-978 on disease activity.","length":379,"tagName":"p"},{"type":"text","content":"“We are pleased to announce the achievement of an important regulatory milestone allowing us to initiate a clinical trial of CLN-978 in rheumatoid arthritis in the second quarter of this year, with leading research institutions in Europe, as we simultaneously advance our systemic lupus erythematosus trial at sites around the globe,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “CLN-978 is the only CD19-targeting T cell engager advancing a global regulatory development plan that includes a U.S. FDA-cleared IND. Delivering the potency of T cell redirecting therapy with the potential for disease modification, CLN-978 offers off-t...